Filipiak Wojciech, Beer Ronny, Sponring Andreas, Filipiak Anna, Ager Clemens, Schiefecker Alois, Lanthaler Simon, Helbok Raimund, Nagl Markus, Troppmair Jakob, Amann Anton
Breath Research Institute of the Leopold Franzens University of Innsbruck, Rathausplatz 4, A-6850 Dornbirn, Austria. Innsbruck Medical University, Anichstraße 35, A-6020 Innsbruck, Austria.
J Breath Res. 2015 Jan 5;9(1):016004. doi: 10.1088/1752-7155/9/1/016004.
Existing methods for the early detection of infections in mechanically ventilated (MV) patients at intensive care units (ICUs) are unsatisfactory. Here we present an exploratory study assessing the feasibility of breath VOC analyses for the non-invasive detection of pathogens in the lower respiratory tract of ventilated patients. An open uncontrolled clinical pilot study was performed by enrolling 28 mechanically ventilated (MV) patients with severe intracranial disease, being at risk for the development of or already with confirmed ventilation-associated pneumonia (VAP). The recently developed sampling technique enabled the collection of breath gas with a maximized contribution of alveolar air directly from the respiratory circuit under continuous capnography control, adsorptive preconcentration and final analysis by means of gas chromatography-mass spectrometry (GC-MS).VAP was confirmed in 22/28 preselected patients (78%). The most common microorganisms were Staphylococcus aureus (5/22 VAP patients), Escherichia coli (5/22 VAP patients) and Candida spp. (5/22 VAP patients). 12/32 metabolites released by S. aureus in our previous in vitro studies were also detected in the end-tidal air of VAP patients infected with this pathogen. A similar overlap was seen in Candida albicans infections (8/29 VOCs). Moreover, the concentration profile of selected compounds correlated with the course of the infection.This prospective pilot study provides proof of the concept that the appearance and the concentration profile of pathogen-derived metabolites (elucidated from in vitro experiments) in the breath of ventilated patients during clinically confirmed VAP correlates with the presence of a particular pathogen.
重症监护病房(ICU)中用于机械通气(MV)患者感染早期检测的现有方法并不令人满意。在此,我们开展了一项探索性研究,评估呼气挥发性有机化合物(VOC)分析用于无创检测通气患者下呼吸道病原体的可行性。我们进行了一项开放的非对照临床试验,纳入了28例患有严重颅内疾病的机械通气(MV)患者,这些患者有发生或已确诊呼吸机相关性肺炎(VAP)的风险。最近开发的采样技术能够在持续二氧化碳监测控制下,直接从呼吸回路收集肺泡气贡献最大化的呼出气,进行吸附预浓缩并最终通过气相色谱 - 质谱联用仪(GC - MS)进行分析。在28例预先选定的患者中有22例(78%)确诊为VAP。最常见的微生物是金黄色葡萄球菌(22例VAP患者中有5例)、大肠杆菌(22例VAP患者中有5例)和念珠菌属(22例VAP患者中有5例)。在我们之前的体外研究中金黄色葡萄球菌释放的32种代谢产物中的12种,也在感染该病原体的VAP患者的终末潮气中被检测到。白色念珠菌感染中也观察到类似的重叠情况(29种VOC中有8种)。此外,选定化合物的浓度曲线与感染进程相关。这项前瞻性试验研究证明了这样一个概念,即在临床确诊的VAP期间,通气患者呼出气体中病原体衍生代谢产物的出现和浓度曲线(从体外实验中阐明)与特定病原体的存在相关。